tradingkey.logo

Oncology Institute Inc

TOI
3.545USD
-0.265-6.96%
Close 11/07, 16:00ETQuotes delayed by 15 min
330.68MMarket Cap
LossP/E TTM

Oncology Institute Inc

3.545
-0.265-6.96%

More Details of Oncology Institute Inc Company

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Oncology Institute Inc Info

Ticker SymbolTOI
Company nameOncology Institute Inc
IPO dateMar 13, 2020
CEODr. Daniel Virnich, M.D.
Number of employees825
Security typeOrdinary Share
Fiscal year-endMar 13
Address18000 Studebaker Rd
CityCERRITOS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code90703
Phone15627353226
Websitehttps://theoncologyinstitute.com/
Ticker SymbolTOI
IPO dateMar 13, 2020
CEODr. Daniel Virnich, M.D.

Company Executives of Oncology Institute Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.18M
-1.69%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.17K
-0.68%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
198.04K
--
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
193.04K
-0.92%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
183.35K
--
Mr. Gabriel Ling
Mr. Gabriel Ling
Independent Director
Independent Director
109.06K
--
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
--
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--
Ms. Karen M. Johnson
Ms. Karen M. Johnson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.18M
-1.69%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.17K
-0.68%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
198.04K
--
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
193.04K
-0.92%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
183.35K
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
By BusinessUSD
Name
Revenue
Proportion
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%

Shareholding Stats

Updated: Sat, Oct 4
Updated: Sat, Oct 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
M33 Growth LLC
9.12%
The Vanguard Group, Inc.
4.86%
OncologyCare Partners LLC
4.40%
Deerfield Management Company, L.P.
3.59%
BlackRock Institutional Trust Company, N.A.
3.20%
Other
74.83%
Shareholders
Shareholders
Proportion
M33 Growth LLC
9.12%
The Vanguard Group, Inc.
4.86%
OncologyCare Partners LLC
4.40%
Deerfield Management Company, L.P.
3.59%
BlackRock Institutional Trust Company, N.A.
3.20%
Other
74.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.49%
Hedge Fund
9.69%
Venture Capital
9.17%
Investment Advisor/Hedge Fund
6.83%
Individual Investor
4.49%
Corporation
4.40%
Research Firm
0.43%
Private Equity
0.27%
Bank and Trust
0.16%
Other
48.09%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
144
40.27M
43.06%
-3.18M
2025Q2
119
39.72M
44.51%
-19.63M
2025Q1
137
46.36M
52.04%
-13.47M
2024Q4
138
45.05M
59.62%
-19.81M
2024Q3
139
50.89M
67.39%
-11.59M
2024Q2
143
57.80M
76.77%
-3.05M
2024Q1
146
56.10M
75.87%
-3.90M
2023Q4
143
57.48M
77.79%
-4.30M
2023Q3
176
58.70M
79.97%
-14.73M
2023Q2
180
58.28M
81.90%
-25.39M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
M33 Growth LLC
8.52M
9.12%
-5.15M
-37.65%
Sep 04, 2025
The Vanguard Group, Inc.
4.28M
4.58%
+2.53M
+144.52%
Jun 30, 2025
OncologyCare Partners LLC
4.11M
4.4%
--
--
Mar 26, 2025
Deerfield Management Company, L.P.
3.36M
3.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
3.2%
+2.74M
+1088.12%
Jun 30, 2025
CenterBook Partners LP
715.90K
0.77%
+715.90K
--
Jun 30, 2025
Balyasny Asset Management LP
2.52M
2.69%
+371.00K
+17.28%
Jun 30, 2025
Josh Arnold Investment Consultant, LLC
2.45M
2.62%
+457.65K
+23.01%
Jun 30, 2025
Marshall Wace LLP
1.48M
1.58%
+1.48M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
1.37%
+893.70K
+231.68%
Jun 30, 2025
View more

Related ETFs

Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Vanguard US Momentum Factor ETF
0.1%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Vanguard US Momentum Factor ETF
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI